The Centers for Medicare & Medicaid Services released its 2027 Medicare Advantage and Part D Star Ratings on October 8, 2026. The results are available for this fall’s enrollment decisions and will affect 2028 Medicare Advantage quality bonus payments.
For health plans, the release creates an immediate need to explain performance to members and a longer-term task: determine which operational improvements deserve investment. Quality, finance, pharmacy and member-service teams should work from the same contract-level results, while keeping their planning timelines distinct.
CMS reported the following results for Medicare Advantage contracts that include prescription drug coverage, known as MA-PD contracts:
| Indicator | 2027 result |
|---|---|
| Contracts earning at least four stars | 188, approximately 37% |
| Current MA-PD enrollment in those contracts | Approximately 71% |
| Enrollment-weighted average overall rating | 3.99 |
| Contracts earning five stars | 15 |
The comparable average in CMS’s updated 2026 figures was 4.01. CMS rating distribution
The distinction between 37% of contracts and 71% of enrollment matters. The first figure counts contracts; the second reflects their membership. Together, they indicate that enrollment is concentrated in higher-rated contracts. Neither figure describes every insurer’s performance or the choices available in every local market.
CMS reports ratings at the contract level. Organizations should therefore examine the contracts behind their products before making company-wide comparisons.
The dates also require careful interpretation:
| Date or period | What it means |
|---|---|
| October 8, 2026 | Publication of the 2027 ratings |
| October 15–December 7, 2026 | Medicare’s annual Open Enrollment period |
| January 1, 2027 | Effective date for coverage changes made during that enrollment period |
| 2028 | Medicare Advantage quality bonus payment year affected by these ratings |
CMS specifies the release and bonus-payment timing, while Medicare.gov explains enrollment dates and when coverage changes take effect.
“2027” does not mean the ratings measure care delivered throughout 2027. CMS’s technical notes identify different data periods: many clinical measures use 2025 data, while patient-experience surveys include March–May 2026 responses. This lag matters when evaluating whether a recently introduced improvement program could have influenced the published results.
Several changes to the measure set also deserve attention. The 2027 materials include measures addressing concurrent opioid and benzodiazepine use and multiple anticholinergic medications in older adults. A revised functional-status assessment measure returns, and colorectal cancer screening uses a revised specification. Physical- and mental-health outcome measures each carry a weight of three.
For operational planning, US Health Insights recommends five priorities:
- Build a contract-level explanation of what changed. Begin with the underlying results for each measure. Identify where performance improved, where it deteriorated and where changes in methodology affected comparisons. CMS’s rating thresholds, known as cut points, and calculation rules matter when interpreting movement between star levels. A useful internal review should distinguish changes in measured performance from changes in how that performance translates into stars. Assign an owner to each material issue and document the evidence needed to confirm its cause. This makes the review actionable for operational teams.
- Refresh pharmacy and care-management priorities. Use the revised measure set to check whether existing worklists, reporting definitions and responsibilities still align. Pharmacy leaders can review how medication concerns reach prescribers; care-management leaders can examine whether assessment findings lead to documented follow-up. Prioritize interventions according to patient need, measurable service gaps and operational feasibility. A higher measure weight can inform planning, but it should not become the sole reason to fund a clinical program. For each intervention, specify the eligible population, responsible team, expected action and evidence of completion. Avoid assuming that a new outreach campaign will automatically produce a higher future rating.
- Review appeals data alongside appeals operations. CMS’s 2027 methodology uses Part C reporting data to check the completeness of Independent Review Entity data for appeals measures, with scaled reductions when specified criteria apply. Plans should reconcile their reporting with operational records and investigate discrepancies. A practical review would trace selected cases from receipt through disposition, identify missing information and assign responsibility for correction.This work should involve both the team managing appeals and the team submitting the data.
- Give finance teams a clearly labeled planning model. Finance leaders should record the relevant rating year, payment year and contract in every scenario. Keep assumptions about membership, local markets and future operating performance visible so decision-makers can understand what drives a forecast.The national average alone cannot establish an individual organization’s revenue effect. Any financial estimate requires the organization’s own contract and payment information. For background on the separate annual payment announcement, see our explainer on 2027 Medicare Advantage payment changes.
- Prepare member-facing explanations before enrollment questions increase. Review website copy, broker materials and service scripts for consistent descriptions of the rating year and the relevant contract. Compliance teams should check rating claims against current CMS marketing requirements. Member-service training should also prepare staff to answer practical questions about doctors, medicines, premiums and benefits. A rating can support a coverage discussion, but members still need information about whether a particular product meets their needs.
